re QURE's HemoB trial (news from 6/22) | SGMO Message Board Posts


Sangamo Therapeutics, Inc.

  SGMO website

SGMO   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  158515 of 159354  at  6/24/2021 10:09:43 AM  by

Watsonncrick

The following message was updated on 6/24/2021 10:10:34 AM.

 In response to msg 158513 by  egomaniakos
view thread

Re: re QURE's HemoB trial (news from 6/22)

  
One would think (hope) that question should be moving to the top of the list for the next UniQure earnings call in the Q&A portion w/ analysts. That is, if an analyst report prior to the next UniQure earnings call doesn't specifically address it after the lead-in "we spoke with management...."
 
I'd definitely think one analyst would be savvy enough to try to pull more color on the FDA steady-state specifics from UniQure in the next earnings call..  
 
Then, of course, the question remains as to how universally applicable that "steady-state as defined by FDA for UniQure's HemoB gene therapy" is w/ respect to what could be applicable to HemoA gene therapy. 
 
I guess that was my long-winded way of saying...we'll see. 
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 5  
   Views: 0 []
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


Financial Market Data provided by
.
Loading...